Press releases

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in December and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention. The...

Bactiguard’s endotracheal tubes approved in India

The product approval for Bactiguard's endotracheal tubes has been announced by the Indian Ministry of Health & Family Welfare. This means that Bactiguard can offer its complete portfolio of products for effective and safe infection prevention in one of the largest and fastest growing markets in the world.  The Central Drugs Standard Control...

Nomination Committee appointed for the Annual General Meeting 2018

The Annual General Meeting of Bactiguard Holding AB (publ) will be held on Wednesday 16 May, 2018 in Botkyrka.  In accordance with the instructions for the Nomination Committee in Bactiguard Holding AB (publ), the Nomination Committee shall consist of four members. The chairman of the Board of Directors shall contact the three largest...

Interim report for Q3 2017

Regulatory

We can now put eight quarters of rising sales based on rolling twelve-month figures behind us, which is very positive. This means that more and more patients have access to effective and safe infection prevention, not least in Sweden where we have recently won another tender. The value of delivered products increased by close to 50% in the...

Bactiguard secures three-year financing

Regulatory

Bactiguard has received a commitment for a three-year credit facility of SEK 180 million from Skandinaviska Enskilda Banken (SEB), in the form of an overdraft facility of SEK 30 million and a term loan of SEK 150 million. The credit facility replaces current bank financing as well as a loan from the company's main shareholders. "For some time,...

Invitation to presentation of Bactiguard’s interim report on November 9, 2017

Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday, November 9, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on November 9. CEO Christian Kinch and CFO Cecilia Edström will present the interim report and answer questions. The...

Bactiguard enters new partnership in India

Bactiguard has entered a partnership with Neon Laboratories Limited (“Neon”) for the north, west and east zones of India, covering a majority of the Indian population.  The Neon Group is a family-owned, manufacturer and distributor of pharmaceuticals and medical devices, with a turnover of more than 85 MUSD. The company started operations in...

Bactiguard wins another tender in Sweden

Bactiguard has won a tender for urinary catheters for the Västra Götaland region (VGR) in Sweden, which enables healthcare providers in both primary and secondary care and 49 municipalities in the region to purchase Bactiguards’ urinary catheters for infection prevention. The contract is valid for 2 years and can be extended for another 2...

Bactiguard’s central venous catheters approved in Hong Kong

The Hong Kong product approval for Bactiguard's central venous catheters for infection prevention has been announced by the Medical Device Control Office. Hong Kong is a small, but strategically important market, as it serves as a reference for new approvals and market acceptance in neighbouring China.  The Medical Device Control Office in Hong...

New major order from China

Regulatory

Bactiguard has received a new order from China of 100 000 urinary catheters for infection prevention, which will be delivered in September and generate revenues of some 3 million SEK. We have received a new order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters for infection prevention,...

Bactiguard’s central venous catheters approved in India

Regulatory

The product approval for Bactiguard's central venous catheters has been announced by the Indian Ministry of Health & Family Welfare. This provides new opportunities for Bactiguard in providing effective infection prevention in one of the largest and fastest growing markets in the world.  The Central Drugs Standard Control Organisation...

Bactiguard appoints new CFO

Regulatory

Bactiguard Holding AB (publ) has appointed Cecilia Edström, today Senior Vice President Sales and New Business, as acting Chief Financial Officer (CFO). She succeeds Fredrik Järrsten, who will leave Bactiguard to assume a new CFO role in another company. Cecilia Edström will assume her new position on 15 September. ”Fredrik Järrsten has...

Interim report for Q2 2017

Regulatory

Bactiguard saves lives by preventing healthcare associated infections. With the development in the second quarter, sales of our own product portfolio have now increased for seven consecutive quarters, based on rolling twelve-month figures. This means that more patients have access to effective and safe infection prevention. The value of delivered...

Invitation to presentation of Bactiguard’s interim report on August 10, 2017

Bactiguard Holding AB (publ) publishes the interim report for the second quarter on Thursday, August 10, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on August 10. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The...

New Team Bactiguard

Good to Great Tennis Academy and Swedish medtech company Bactiguard AB have today announced that they are continuing to strengthen the development of future tennis talent in Sweden by focusing on younger players between 13 to 14 years of age. Together, Good to Great Tennis Academy and Bactiguard have created a new Team Bactiguard consisting of...

New major order from China

Regulatory

Bactiguard has received a third major order from China of 100 000 Bactiguard coated Foley catheters for infection prevention, which will be delivered in June and generate revenues of some 3 million SEK. We have received a third major order from our distributor Jian An Pharmaceuticals. The order is for 100 000 Bactiguard coated Foley catheters...

Bactiguard wins another tender in Sweden

Bactiguard has won a tender for urinary catheters for the southern region (Region Skåne) in Sweden, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters from 1 August 2017. The contract initially runs until 30 April 2018 and can be extended on an annual basis until 30...

Bactiguard enters new partnership for South Africa

Bactiguard has entered partnership with Surgical Innovations Pty Ltd (“SI”), a company within the Medical arm of Ascendis Health, the JNB listed healthcare giant and leading supplier to the healthcare sector in South Africa.  “Surgical Innovations is a leading provider of medical devices to both public and private hospitals, representing...

Bactiguard enters new partnership for Italy

Bactiguard has entered partnership with Gada Italia Srl (“Gada”), a specialized and leading distributor of medical devices and integrated healthcare services.  “The Gada group is a leading provider of integrated healthcare solutions to the public and private hospitals in Italy and we are confident that they have the competence and...

Bactiguard wins tender for Stockholm

Bactiguard has won a tender for urinary catheters for the Stockholm county council, which enables healthcare providers in both primary and secondary care to purchase Bactiguards’ anti-infective urinary catheters. The contract is valid for 2 years and can be extended for another 2 years. "The Stockholm county council is Sweden’s largest region...

Bactiguard Holding AB’s (publ) Annual General Meeting

At Bactiguard Holding AB’s (publ) Annual General Meeting on May 18, the following resolutions were made: The Annual General Meeting adopted the income statement and balance sheet for 2016. It was decided that no dividend for the financial year 2016 will be paid and that the company's loss (for the year) will be carried forward. The Board of...

Interim report for Q1 2017

Regulatory

Strong financial start in 2017. Revenue grew 58 % in the first quarter and we reached an EBITDA margin of 33 %. The reason for the improved results, besides a new licensing deal, is that we have higher revenues from C.R. Bard and continued cost control. The volume of products sold from our own portfolio is lower than last year, but the product...

Bactiguard appoints new distributor in Brazil

Bactiguard signs distribution agreement and enters partnership with Biodina for Brazil.  “Biodina has a very strong track record of successfully introducing new and advanced products on the Brazlian market and we are very happy to have them as our partner. We have not been satisfied with the development of Bactiguard sales in Brazil and we...

Invitation to presentation of Bactiguard’s interim report on May 4, 2017

Bactiguard Holding AB (publ) publishes the interim report for the first quarter on Thursday, May 4, 2017 at 8:00 CET. In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on May 4. CEO Christian Kinch and CFO Fredrik Järrsten will present the interim report and answer questions. The report and a...

Bactiguard’s Annual Report 2016

The annual report for Bactiguard Holding AB (publ) 2016 is now available at www.bactiguard.com The annual report is available as a downloadable PDF document in both Swedish and English. A printed version of the report will be available from May 5 and can be ordered at info@bactiguard.se. This information is information that Bactiguard Holding AB...

Notice to attend the Annual General Meeting of Bactiguard Holding AB

The shareholders of Bactiguard Holding AB (publ), company reg. no. 556822-1187 (“Bactiguard”) are hereby given notice to attend the Annual General Meeting to be held on Thursday, 18 May 2017 at 2:00 PM at the company´s office at Alfred Nobels Allé 150 in Tullinge. Registration commences at 1 PM. Right to participate and notice of intent to...

Bactiguard wins tender in Sweden

Bactiguard has won a tender for urinary catheters covering the Swedish county Kalmar. The contract is an extension of the previous agreement, lasts for 4 years and enables healthcare providers to purchase Bactiguards’ anti-infective urinary catheters. "The Kalmar region has been using our products for the last 2 years and recently decided to...

Year-end report 2016 Bactiguard Holding AB

Regulatory

In many ways, 2016 was a good year for Bactiguard. We exceeded our goal of doubling the volume of products sold in our own portfolio by a wide margin and delivered approx. 418,000 units. We made a breakthrough in China and India, now our two largest markets, and we entered several European markets, while advancing our position in the domestic...

Bactiguard enters new therapeutic area through license agreement

Regulatory

Bactiguard and Smartwise Sweden AB (Smartwise) have entered into a joint development project for advanced, Bactiguard-coated vascular injection catheters. At the same time, a license agreement has been signed. Smartwise will pay USD 2.5 million, for the exclusive and global right to the Bactiguard technology for this application, payable in...

Invitation to presentation of Bactiguard’s year end report for 2016 on February 9, 2017

  Bactiguard Holding AB (publ) publishes the year end report for 2016 on Thursday, February 9, 2017 at 8:00 CET.   In connection with this, a conference call for investors, analysts and media will be held at 10:00 CET on February 9. CEO Christian Kinch and CFO Fredrik Järrsten will present the report and answer questions. The year end...

Bactiguard expands in the Middle East

  Bactiguard signs distribution agreement and enters partnership with Heal Pharma for Egypt. The product registration has been initiated and market launch is planned for the second quarter of 2017.   “Egypt is the most populous country in the Arab world, with major challenges in the healthcare sector. We are convinced that...